Tenpoint Therapeutics, Ltd. has announced that YUVEZZI™ (carbachol and brimonidine tartrate ophthalmic solution) 2.75%/0.1% is now available in the United States for the treatment of presbyopia in adults.

Presbyopia, the gradual loss of close-up vision that typically begins around age 45, affects about 128 million people in the US and two billion people globally (1, 2, 3).

“With the availability of YUVEZZI, we are proud to offer adults with presbyopia a differentiated, one drop, once-daily eye drop that improves near vision,” said Henric Bjarke, Chief Executive Officer of Tenpoint Therapeutics. “[It] is now broadly available through both our e-pharmacy partner and at retail pharmacies, maximizing flexibility for patients. Developed in close partnership with eye care professionals, YUVEZZI was intentionally designed to address real-world needs of people experiencing the effects of aging eyes, and we are excited to now bring this therapy to patients across the U.S.”

YUVEZZI is the first and only dual-agent eye drop approved that combines two active ingredients, carbachol and brimonidine tartrate, that work together to deliver robust and durable efficacy, tolerability, and safety. It is prescribed by eye care professionals, and patients can fill prescriptions nationwide through our e-pharmacy partner PHILRx or any local retail pharmacy of their choice.

“As we age, blurry close-up vision can turn simple, everyday moments like reading a text, checking a receipt or reviewing a menu, into a frustrating challenge,” said Carol Kearney, Chief Commercial Officer of Tenpoint Therapeutics. “YUVEZZI is designed to help adults see up close more clearly with the ease of a single drop, once-daily dosing, providing a new option for those who want to spend less time searching for reading glasses during work, at home, and on the go."